RX Biosyent Inc

BioSyent Inc. ("BioSyent") (TSX VENTURE:RX) today announced it has filed revised
Financial Statements for the second quarter ending June 30, 2010, due to a
technical error in its Consolidated Statement of Cash Flows.


In the Consolidated Statement of Cash Flows filed on August 17, 2010, the
figures in the columns under the title "For the six months ended June 30" are
correct. The figures under the title "For the three months ended June 30" were
erroneous. A corrected Consolidated Statement of Cash Flows has been filed on
www.sedar.com. The error and subsequent correction have no impact on the
reported Income Statement or Balance Sheet.


BioSyent Inc. is a publicly traded specialty pharmaceutical company whose wholly
owned subsidiary, BioSyent Pharma Inc., sources, acquires or in-licences
pharmaceutical products and markets these products in Canada. Wholly owned
BioSyent subsidiary Hedley Technologies Ltd. operates the company's legacy
business marketing bio and health friendly non-chemical insecticides. BioSyent
common shares are listed for trading on the TSX Venture Exchange (TSXV) under
the symbol RX. 


This press release may contain information or statements that are
forward-looking. The contents herein represent our judgment, as at the release
date, and are subject to risks and uncertainties that may cause actual results
or outcomes to be materially different from the forward-looking information or
statements. Potential risks may include, but are not limited to, those
associated with clinical trials, product development, future revenue,
operations, profitability and obtaining regulatory approvals.

Biosyent (TSXV:RX)
Historical Stock Chart
From May 2024 to Jun 2024

Biosyent (TSXV:RX)
Historical Stock Chart
From Jun 2023 to Jun 2024